Condition
Hormone Receptor-Positive Breast Cancer
ClinicalTrials.gov condition label
Clinical trials
14 shownNeoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast CancerNCT07796880 · 2026-09-14
RECRUITINGCDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant TreatmentNCT07366112 · 2026-04-20
RECRUITINGObservational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without DiarrheaNCT07264998 · 2025-12-21
RECRUITINGClinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerNCT07856225 · 2025-12-01
RECRUITINGctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast CancerNCT06970912 · 2025-08-01
RECRUITINGEntinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailureNCT07708194 · 2025-06-23
RECRUITINGTirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast CancerNCT06518837 · 2024-10-30
RECRUITINGPredicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyNCT06805812 · 2023-05-01
RECRUITINGReal-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXdNCT07073755 · 2023-01-01
RECRUITINGSOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast CancersNCT07844759 · 2027-01-01
NOT_YET_RECRUITINGEstradiol Levels According to Body Mass Index in Premenopausal Patients With Breast CancerNCT07833501 · 2026-09-03
NOT_YET_RECRUITINGA Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast CancerNCT07294339 · 2026-04-01
NOT_YET_RECRUITINGA Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast CancerNCT06878248 · 2025-04-17
TERMINATEDStudy to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple MyelomaNCT01177397 · 2010-07-20
COMPLETEDCommon interventions
endocrine therapyDRUG2AbemaciclibDRUG1Anti-HER2 TherapyDRUG1Aromatase Inhibitor (AI)DRUG1CC-223DRUG1CDK4/6 inhibitor with endocrine therapyDRUG1CDK4/6 InhibitorsDRUG1CulmerciclibDRUG1Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided TherapyDRUG1entinostatDRUG1PalbociclibDRUG1PyrotinibDRUG1RibociclibDRUG1Sham AcupunctureOTHER1Standard Breast Cancer TreatmentOTHER1Stereotactic Radiation TherapyRADIATION1Taxane-Based Neoadjuvant ChemotherapyDRUG1TirzepatideDRUG1True AcupunctureOTHER1Two Component Product CLBR001 + ABBV-461BIOLOGICAL1
Leading sponsors
Peking University People's Hospital3Calibr, a division of Scripps Research1Celgene1D'Or Institute for Research and Education1Fondazione IRCCS Istituto Nazionale dei Tumori, Milano1Fundación Santa Fe de Bogota1Hubei Cancer Hospital1Hunan Cancer Hospital1Renaissance Institute of Precision Oncology and Radiosurgery1Rutgers, The State University of New Jersey1Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1Tianjin Medical University Cancer Institute and Hospital1
Trial status mix
RECRUITING9
NOT_YET_RECRUITING3
COMPLETED1
TERMINATED1
Phase mix
PHASE26
PHASE13
NA2
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.